

NOVAVAX INC  
Form 8-K  
April 29, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) April 25, 2013**

**NOVAVAX, INC.**

---

**(Exact name of Registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of incorporation or  
organization)**

**0-26770**  
**(Commission File  
Number)**

**22-2816046**  
**(I.R.S. Employer Identification  
No.)**

**9920 Belward Campus Drive**  
**20850**  
**Rockville, Maryland**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (240) 268-2000**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 25, 2013, Fred Driscoll gave notice of his intention to resign as Vice President, Chief Financial Officer of Novavax, Inc. (the “Company”), effective May 17, 2013. Mr. Driscoll, a resident of the Boston area, plans to pursue an opportunity with a Massachusetts-based specialty pharmaceutical company. The Company thanks Fred for his many years of service and wishes him well with his new opportunity. The Company has begun recruitment for a senior level financial executive.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novavax, Inc.

(Registrant)

April 29, 2013 By: /s/ John A. Herrmann III  
Name: John A. Herrmann III  
Title: Vice President, General Counsel and Corporate Secretary